Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Liver segment imaging using monocyte sequestration: a potential tool for fluorescence-guided liver surgery.

Qian B, Kyuno D, Schäfer M, Gross W, Mehrabi A, Ryschich E.

Theranostics. 2018 Nov 29;8(22):6101-6110. doi: 10.7150/thno.29223. eCollection 2018.

2.

Microsurgical Technique of Locoregional Injection into the Hepatic Artery in Tumor-Bearing Mice.

Qian B, Strübing F, Wang Z, Mehrabi A, Ryschich E.

Eur Surg Res. 2018;59(5-6):339-348. doi: 10.1159/000494429. Epub 2018 Nov 22.

PMID:
30466084
3.

Therapeutic Targeting Cancer-Initiating Cell Markers by Exosome miRNA: Efficacy and Functional Consequences Exemplified for claudin7 and EpCAM.

Kyuno D, Zhao K, Bauer N, Ryschich E, Zöller M.

Transl Oncol. 2019 Feb;12(2):191-199. doi: 10.1016/j.tranon.2018.08.021. Epub 2018 Oct 28.

4.

Phenomenon of Endothelial Antibody Capture: Principles and Potential for Locoregional Targeting of Hepatic Tumors.

Winkler N, Strübing F, Groß W, Mier W, Ryschich E.

Hepatology. 2018 Nov;68(5):1804-1816. doi: 10.1002/hep.30072. Epub 2018 Sep 21.

PMID:
29734469
5.

Electrochemical Effects after Transarterial Chemoembolization in Combination with Percutaneous Irreversible Electroporation: Observations in an Acute Porcine Liver Model.

Vollherbst D, Bertheau RC, Fritz S, Mogler C, Kauczor HU, Ryschich E, Radeleff BA, Pereira PL, Sommer CM.

J Vasc Interv Radiol. 2016 Jun;27(6):913-921.e2. doi: 10.1016/j.jvir.2016.02.001. Epub 2016 Apr 18.

PMID:
27103147
6.

Impact of wall shear stress and ligand avidity on binding of anti-CD146-coated nanoparticles to murine tumor endothelium under flow.

Thomann S, Baek S, Ryschich E.

Oncotarget. 2015 Nov 24;6(37):39960-8. doi: 10.18632/oncotarget.5662.

7.

Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.

Zhang Y, Liu L, Fan P, Bauer N, Gladkich J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, Hinz U, Gross W, Fortunato F, Herr I.

Oncotarget. 2015 Apr 30;6(12):9999-10015.

8.

Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.

Karakhanova S, Ryschich E, Mosl B, Harig S, Jäger D, Schmidt J, Hartwig W, Werner J, Bazhin AV.

Br J Cancer. 2015 Mar 17;112(6):1027-36. doi: 10.1038/bjc.2015.72.

9.

Selective targeting of liver cancer with the endothelial marker CD146.

Thomann S, Longerich T, Bazhin AV, Mier W, Schemmer P, Ryschich E.

Oncotarget. 2014 Sep 30;5(18):8614-24.

10.

Anti-inflammatory functions of protein C require RAGE and ICAM-1 in a stimulus-dependent manner.

Braach N, Buschmann K, Pflaum J, Hudalla H, Koch L, Ryschich E, Poeschl J, Frommhold D.

Mediators Inflamm. 2014;2014:743678. doi: 10.1155/2014/743678. Epub 2014 May 4.

11.

Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.

Hartmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Ryschich E.

Clin Cancer Res. 2014 Jul 1;20(13):3422-33. doi: 10.1158/1078-0432.CCR-13-2972. Epub 2014 Apr 24.

12.

The role of β2-integrins and CD44 in intrahepatic leukocyte sequestration.

Castro-Santa E, Salnikova O, Ryschich E.

J Surg Res. 2013 Oct;184(2):1070-5. doi: 10.1016/j.jss.2013.04.064. Epub 2013 May 18.

PMID:
23726757
13.

Endothelial plasticity governs the site-specific leukocyte recruitment in hepatocellular cancer.

Salnikova O, Breuhahn K, Hartmann N, Schmidt J, Ryschich E.

Int J Cancer. 2013 Nov 15;133(10):2372-82. doi: 10.1002/ijc.28268. Epub 2013 Jun 10.

14.

Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential.

Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Büchler MW, Herr I.

PLoS One. 2012;7(9):e46391. doi: 10.1371/journal.pone.0046391. Epub 2012 Sep 26.

15.

The role of the tumor endothelium in leukocyte recruitment in pancreatic cancer.

Schmidt J, Mocevicius P, Werner J, Ryschich E.

Surgery. 2012 Sep;152(3 Suppl 1):S89-94. doi: 10.1016/j.surg.2012.05.027. Epub 2012 Jul 6. Review.

PMID:
22770953
16.

New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.

Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW, Moldenhauer G, Herr I.

Clin Cancer Res. 2012 Feb 15;18(4):1028-38. doi: 10.1158/1078-0432.CCR-11-2767. Epub 2012 Jan 6.

17.

Blockade of leukocyte haptokinesis and haptotaxis by ketoprofen, diclofenac and SC-560.

Paskauskas S, Parseliunas A, Kerkadze V, Nobiling R, Schmidt J, Ryschich E.

BMC Immunol. 2011 Nov 12;12:64. doi: 10.1186/1471-2172-12-64.

18.

αL β2 integrin is indispensable for CD8+ T-cell recruitment in experimental pancreatic and hepatocellular cancer.

Takeichi T, Mocevicius P, Deduchovas O, Salnikova O, Castro-Santa E, Büchler MW, Schmidt J, Ryschich E.

Int J Cancer. 2012 May 1;130(9):2067-76. doi: 10.1002/ijc.26223. Epub 2011 Aug 16.

19.

Chronic alcohol intake increases the severity of pancreatitis induced by acute alcohol administration, hyperlipidemia and pancreatic duct obstruction in rats.

Grauvogel J, Daemmrich TD, Ryschich E, Gebhard MM, Werner J.

Pancreatology. 2010;10(5):603-12. doi: 10.1159/000288707. Epub 2010 Oct 29.

PMID:
20980778
20.

RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo.

Frommhold D, Kamphues A, Hepper I, Pruenster M, Lukic IK, Socher I, Zablotskaya V, Buschmann K, Lange-Sperandio B, Schymeinsky J, Ryschich E, Poeschl J, Kupatt C, Nawroth PP, Moser M, Walzog B, Bierhaus A, Sperandio M.

Blood. 2010 Aug 5;116(5):841-9. doi: 10.1182/blood-2009-09-244293. Epub 2010 Apr 20.

21.

4-dimensional intravital microscopy: a new model for studies of leukocyte recruitment and migration in hepatocellular cancer in mice.

Takeichi T, Engelmann G, Mocevicius P, Schmidt J, Ryschich E.

J Gastrointest Surg. 2010 May;14(5):867-72. doi: 10.1007/s11605-010-1179-x. Epub 2010 Mar 6.

PMID:
20229071
22.

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.

Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, Ryschich E, Büchler MW, Herr I, Moldenhauer G.

J Cell Mol Med. 2009 Sep;13(9B):4023-33. doi: 10.1111/j.1582-4934.2009.00723.x.

23.

Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer.

Ryschich E, Khamidjanov A, Kerkadze V, Büchler MW, Zöller M, Schmidt J.

Pancreas. 2009 Oct;38(7):804-10. doi: 10.1097/MPA.0b013e3181b9dfda.

PMID:
19893454
24.

Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.

Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G.

J Surg Res. 2010 Apr;159(2):705-13. doi: 10.1016/j.jss.2008.07.035. Epub 2008 Aug 27.

PMID:
19482307
25.

Intracapillary leucocyte accumulation as a novel antihaemorrhagic mechanism in acute pancreatitis in mice.

Ryschich E, Kerkadze V, Deduchovas O, Salnikova O, Parseliunas A, Märten A, Hartwig W, Sperandio M, Schmidt J.

Gut. 2009 Nov;58(11):1508-16. doi: 10.1136/gut.2008.170001. Epub 2009 May 20.

PMID:
19460768
26.

Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter.

Salnikov AV, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Büchler MW, Schemmer P, Herr I.

Cancer Lett. 2009 Mar 18;275(2):185-93. doi: 10.1016/j.canlet.2008.10.015. Epub 2008 Nov 20.

PMID:
19026485
27.

Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.

Zhu Y, Tibensky I, Schmidt J, Ryschich E, Märten A.

J Immunother. 2008 Sep;31(7):599-606. doi: 10.1097/CJI.0b013e3181818769.

PMID:
18600184
28.

Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.

Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K.

Hepatology. 2008 Jul;48(1):146-56. doi: 10.1002/hep.22297.

PMID:
18537183
29.

Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer.

Kallifatidis G, Beckermann BM, Groth A, Schubert M, Apel A, Khamidjanov A, Ryschich E, Wenger T, Wagner W, Diehlmann A, Saffrich R, Krause U, Eckstein V, Mattern J, Chai M, Schütz G, Ho AD, Gebhard MM, Büchler MW, Friess H, Büchler P, Herr I.

Cancer Gene Ther. 2008 Apr;15(4):231-40. doi: 10.1038/sj.cgt.7701097. Epub 2008 Jan 18.

PMID:
18202717
30.

Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.

Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jäger D, Büchler MW, Märten A.

J Immunother. 2008 Jan;31(1):28-33.

PMID:
18157009
31.

Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma.

Serba S, Schmidt J, Wentzensen N, Ryschich E, Märten A.

Gut. 2008 Mar;57(3):344-51. Epub 2007 Aug 3.

PMID:
17675324
32.

Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma.

Eisold S, Schmidt J, Ryschich E, Gock M, Klar E, von Knebel Doeberitz M, Linnebacher M.

Pancreas. 2007 Jul;35(1):63-72.

PMID:
17575547
33.

Taurine protects from liver injury after warm ischemia in rats: the role of kupffer cells.

Kincius M, Liang R, Nickkholgh A, Hoffmann K, Flechtenmacher C, Ryschich E, Gutt CN, Gebhard MM, Schmidt J, Büchler MW, Schemmer P.

Eur Surg Res. 2007;39(5):275-83. Epub 2007 May 22.

PMID:
17519554
34.

Impaired Fas-induced apoptosis of T lymphocytes in patients with abdominal aortic aneurysms.

Zhang J, Böckler D, Ryschich E, Klemm K, Schumacher H, Schmidt J, Allenberg JR.

J Vasc Surg. 2007 May;45(5):1039-46. Epub 2007 Mar 13.

35.

Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029.

Gesierich S, Berezovskiy I, Ryschich E, Zöller M.

Cancer Res. 2006 Jul 15;66(14):7083-94.

36.

Active leukocyte crawling in microvessels assessed by digital time-lapse intravital microscopy.

Ryschich E, Kerkadze V, Lizdenis P, Paskauskas S, Knaebel HP, Gross W, Gebhard MM, Büchler MW, Schmidt J.

J Surg Res. 2006 Oct;135(2):291-6. Epub 2006 Apr 21.

PMID:
16631202
37.

Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer.

Ryschich E, Märten A, Schmidt E, Linnebacher M, Wentzensen N, Eisold S, Klar E, Büchler MW, Schmidt J.

Eur J Cancer. 2006 May;42(7):981-7. Epub 2006 Mar 27.

PMID:
16564167
38.

Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.

Ryschich E, Huszty G, Wentzensen N, Schmidt E, Knaebel HP, Encke J, Märten A, Büchler MW, Schmidt J.

Int J Colorectal Dis. 2007 Feb;22(2):215-23. Epub 2006 Mar 10.

PMID:
16528542
39.

Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma.

Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hämmerling GJ, Ganss R.

Cancer Res. 2006 Jan 1;66(1):198-211.

40.

Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo.

Schmidt J, Ryschich E, Sievers E, Schmidt-Wolf IG, Büchler MW, Märten A.

Cancer. 2006 Feb 15;106(4):759-64.

41.

Enhancement of leukocyte adhesion after percutaneous irradiation in rats with hepatocellular carcinoma.

Maksan SM, Schmidt E, Ryschich E, Harms W, Schmidt J.

World J Gastroenterol. 2005 Apr 7;11(13):1991-4.

42.

Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.

Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, Weitz J, Fröhlich B, Klar E, Büchler MW, Schmidt J.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):498-504.

43.

Disturbance of hepatic and intestinal microcirculation in experimental liver cirrhosis.

Maksan SM, Ryschich E, Ulger Z, Gebhard MM, Schmidt J.

World J Gastroenterol. 2005 Feb 14;11(6):846-9.

44.

Loss of heterozygosity in the HLA class I region in human pancreatic cancer.

Ryschich E, Cebotari O, Fabian OV, Autschbach F, Kleeff J, Friess H, Bierhaus A, Büchler MW, Schmidt J.

Tissue Antigens. 2004 Dec;64(6):696-702.

PMID:
15546343
45.

The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines.

Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E, Schmidt J.

World J Gastroenterol. 2004 Dec 15;10(24):3583-9.

46.
47.

Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.

Ryschich E, Jesnowski R, Ringel J, Harms W, Fabian OV, Saller R, Schrewe M, Engel A, Schmidt J, Löhr M.

Int J Cancer. 2005 Feb 10;113(4):649-53.

48.

Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat.

Maksan SM, Araib PM, Ryschich E, Gebhard MM, Schmidt J.

Dig Dis Sci. 2004 May;49(5):859-65.

PMID:
15259510
49.

Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas.

Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J.

Eur J Cancer. 2004 Jun;40(9):1418-22.

PMID:
15177502
50.

Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background.

Eisold S, Ryschich E, Linnebacher M, Giese T, Nauheimer D, Wild A, Bartsch DK, Büchler MW, Schmidt J.

Cancer. 2004 May 1;100(9):1978-86.

Supplemental Content

Loading ...
Support Center